Spondyloarthritis with inflammatory bowel disease: the latest on biologic and targeted therapies.
Nat Rev Rheumatol
; 19(8): 503-518, 2023 08.
Article
in En
| MEDLINE
| ID: mdl-37386288
ABSTRACT
Spondyloarthritis (SpA) encompasses a heterogeneous group of chronic inflammatory diseases that can affect both axial and peripheral joints, tendons and entheses. Among the extra-articular manifestations, inflammatory bowel disease (IBD) is associated with considerable morbidity and effects on quality of life. In everyday clinical practice, treatment of these conditions requires a close collaboration between gastroenterologists and rheumatologists to enable early detection of joint and intestinal manifestations during follow-up and to choose the most effective therapeutic regimen, implementing precision medicine for each patient's subtype of SpA and IBD. The biggest issue in this field is the dearth of drugs that are approved for both diseases, as only TNF inhibitors are currently approved for the treatment of full-spectrum SpA-IBD. Janus tyrosine kinase inhibitors are among the most promising drugs for the treatment of peripheral and axial SpA, as well as for intestinal manifestations. Other therapies such as inhibitors of IL-23 and IL-17, phosphodiesterase 4 inhibitor, α4ß7 integrin blockers and faecal microbiota transplantation seem to only be able to control some disease domains, or require further studies. Given the growing interest in the development of novel drugs to treat both conditions, it is important to understand the current state of the art and the unmet needs in the management of SpA-IBD.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Biological Products
/
Inflammatory Bowel Diseases
/
Spondylarthritis
Type of study:
Screening_studies
Aspects:
Patient_preference
Limits:
Humans
Language:
En
Journal:
Nat Rev Rheumatol
Journal subject:
REUMATOLOGIA
Year:
2023
Document type:
Article
Affiliation country:
Italia